It’s only fair to share… Zidesamtinib CAS 2739829-00-4 MF C22H22FN7O MW419.5 g/mol (19R)-3-ethyl-16-fluoro-10,19-dimethyl-20-oxa-3,4,9,10,11,23-hexazapentacyclo[19.3.1.02,6.08,12.013,18]pentacosa-1(25),2(6),4,8,11,13(18),14,16,21,23-decaen-22-amine To treat adults with locally advanced or metastatic ROS1-positive non-small cell lung cancer after receiving a ROS1 kinase inhibitor FDA 2026, APPROVALS 2026, Jideytro, NVL-520, NUV-520, NU-520, NVL 520, NUV 520, NU 520, MX5KQV5XHC Zidesamtinib (sold under the brand name Jideytro) is an …
Category «Cancer»
Gedatolisib
It’s only fair to share… Gedatolisib Approvals 3026, FDA 2026, 7/14/2026, Revtorpyk PF-05212384; PF-5212384; PKI-587CAS 1197160-78-3Chemical Formula: C32H41N9O4Molecular Weight: 615.721-(4-{[4-(Dimethylamino)-1-piperidinyl]carbonyl}phenyl)-3-{4-[4,6-di(4-morpholinyl)-1,3,5-triazin-2-yl]phenyl}urea3-{4-[bis(morpholin-4-yl)-1,3,5-triazin-2-yl]phenyl}-1-{4-[4-(dimethylamino)piperidine-1-carbonyl]phenyl}ureaN-[4-[[4-(Dimethylamino)-1-piperidinyl]carbonyl]phenyl]-N’-[4-[4,6-di(4-morpholinyl)-1,3,5-triazin-2-yl]phenyl]ureaгедатолисиб [Russian] [INN]غيداتوليسيب [Arabic] [INN]吉达利塞 [Chinese] [INN] 1-(4-(4-(Dimethylamino)piperidine-1-carbonyl)phenyl)-3-(4-(4,6-dimorpholino-1,3,5-triazin-2-yl)phenyl)urea Urea, N-[4-[[4-(dimethylamino)-1-piperidinyl]carbonyl]phenyl]-N’-[4-(4,6-di-4-morpholinyl-1,3,5-triazin-2-yl)phenyl]- 96265TNH2R In combination with fulvestran, to treat hormone receptor-positive, human epidermal growth factor receptor 2-negative, locally advanced or metastatic breast cancer without a PIK3CA mutation detected following progression on or after treatment …
Imlunestrant
It’s only fair to share… Imlunestrant CAS 2408840-26-4 as tosylate: 2408840-41-3 (5R)-5-[4-[2-[3-(fluoromethyl)azetidin-1-yl]ethoxy]phenyl]-8-(trifluoromethyl)-5H-chromeno[4,3-c]quinolin-2-ol MF C29H24F4N2O3 MW 524.516 FDA 9/25/2025, Inluriyo, LY3484356, LY-3484356, To treat estrogen receptor-positive, human epidermal growth factor receptor 2-negative, estrogen receptor-1-mutated advanced or metastatic breast cancer with disease progression following at least one line of endocrine therapy Imlunestrant, sold under the brand name Inluriyo, is …
Zorifertinib
It’s only fair to share… Zorifertinib AZD 3759 CAS 1626387-80-1, 67SX9H68W2 WeightAverage: 459.91Monoisotopic: 459.1473455 Chemical FormulaC22H23ClFN5O3 [4-(3-chloro-2-fluoroanilino)-7-methoxyquinazolin-6-yl] (2R)-2,4-dimethylpiperazine-1-carboxylate China 2024, APPROVALS 2024, Alpha Biopharma, ASTRA ZENECA, Zorifer, Zorifertinib (AZD3759) is a drug for the treatment of cancer.[1] In China, it was approved in 2024 for locally advanced or metastatic non-small-cell lung cancer (NSCLC) that has epidermal growth factor receptor exon 19 …
Oritinib
It’s only fair to share… Oritinib CHINA 2024, Nanjing Sanhome Pharmaceutical. N-[2-[2-(dimethylamino)ethyl-methylamino]-4-methoxy-5-[[4-(6,7,8,9-tetrahydropyrido[1,2-a]indol-10-yl)pyrimidin-2-yl]amino]phenyl]prop-2-enamide Oritinib is an investigational new drug currently under investigation for its potential use in cancer treatment.[1][2] As a epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, oritinib targets specific enzymes involved in the signaling pathways that regulate cell division and survival, which are often dysregulated in cancer cells.[1] Oritinib (SH-1028), …
Befotertinib
It’s only fair to share… Befotertinib D-0316, 0XT2CPR891 CAS No. : 1835667-63-4, MESYLATE CAS No. 2226167-02-6 Molecular Weight 567.61 Formula C29H32F3N7O2 Befotertinib (D-0316) is an orally active EGFR tyrosine kinase inhibitor. Befotertinib can inhibit the proliferation of tumor cells. Befotertinib can be used in the research of EGFR T790M-positive non-small cell lung cancer (NSCLC). Befotertinib is an orally available inhibitor of the epidermal …
Zongertinib
It’s only fair to share… Zongertinib CAS No. : 2728667-27-2, BI-1810631, BI1810631 Molecular Weight 535.60 Formula C29H29N9O2 FDA 8/8/2025, Hernexeos, To treat adults with unresectable or metastatic non-squamous non-small cell lung cancer whose tumors have HER2 tyrosine kinase domain activating mutations, as detected by an FDA-approved test, and who have received prior systemic therapy Zongertinib is …
Olverembatinib
It’s only fair to share… Olverembatinib WeightAverage: 532.571Monoisotopic: 532.219844002, Chemical FormulaC29H27F3N6O 1421783-64-3 Molecular Weight 724.77 Formula C31H35F3N6O7S2 Olverembatinib (GZD824) dimesylate is a potent and orally active pan-Bcr-Abl inhibitor. Olverembatinib dimesylate potently inhibits a broad spectrum of Bcr-Abl mutants. Olverembatinib dimesylate strongly inhibits native Bcr-Abl and Bcr-AblT315I with IC50s of 0.34 nM and 0.68 nM, respectively. Olverembatinib dimesylate has antitumor activity. Olverembatinib (dimesylate) is …
Alflutinib, Furmonertinib, Firmonertinib
It’s only fair to share… FIRMOMERTINIB, Furmonertinib, Alflutinib CAS 1869057-83-9 , AST 2818, UNII-A49A7A5YN4 N-[2-[[2-(Dimethylamino)ethyl]methylamino]-5-[[4-(1-methyl-1H-indol-3-yl)-2-pyrimidinyl]amino]-6-(2,2,2-trifluoroethoxy)-3-pyridinyl]-2-propenamide N-[2-[2-(dimethylamino)ethyl-methylamino]-5-[[4-(1-methylindol-3-yl)pyrimidin-2-yl]amino]-6-(2,2,2-trifluoroethoxy)pyridin-3-yl]prop-2-enamide C28H31F3N8O2 568.6 g/mol 2-Propenamide, N-[2-[[2-(dimethylamino)ethyl]methylamino]-5-[[4-(1-methyl-1H-indol-3-yl)-2-pyrimidinyl]amino]-6-(2,2,2-trifluoroethoxy)-3-pyridinyl]- Alflutinib is under investigation in clinical trial NCT03452592 (Efficacy and Safety of Alflutinib in Locally Advanced or Metastatic Non-small Cell Lung Cancer Patients With T790M). Firmonertinib is an orally available selective inhibitor of the epidermal growth …
Tibremciclib
It’s only fair to share… Tibremciclib cas 2397678-18-9, GTPL12881 CRB7BT5JDQ 518.6 g/mol, C28H32F2N8 N-[5-[(4-ethylpiperazin-1-yl)methyl]pyridin-2-yl]-5-fluoro-4-[(1R)-6-fluoro-1-methyl-1,2,3,4-tetrahydropyrido[1,2-a]benzimidazol-8-yl]pyrimidin-2-amine Tibremciclib is a CDK4 inhibitor with antineoplastic activity[1]. 13 Sep 2024 Efficacy and adverse event data from a phase III trial in Breast cancer presented at the 49th European Society for Medical Oncology Congress 2024 (ESMO-2024) Cyclin-dependent kinases (CDKs) are a class of serine …